DDInter1008 DDInter621
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy.
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Alpelisib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ketoconazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Escitalopram
Escitalopram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Lorlatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Ketoconazole {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Nintedanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Edoxaban
Ketoconazole {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ketoconazole {u} (Compound) resembles {v} (Compound) Posaconazole
Posaconazole {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Edoxaban
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may lead to a major life threatening interaction when taken with Edoxaban
Ketoconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound) and Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ketoconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Edoxaban
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ketoconazole (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Edoxaban
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Edoxaban
Ketoconazole (Compound) resembles Posaconazole (Compound) and Posaconazole may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Edoxaban